SCHEMBL2815341

SCHEMBL2815341

COc1ccc(-c2cnc3c(NCCN)nc4ccccc4n23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 9/20 0.56
CHUK O15111 9/20 0.56
SYK P43405 4/20 0.48
ERN1 O75460 1/20 0.48
RPS6KA4 O75676 1/20 0.48
PRKD3 O94806 1/20 0.48
CDK1 P06493 1/20 0.48
KIT P10721 1/20 0.48
CDK11B P21127 1/20 0.48
CDK2 P24941 1/20 0.48
TYK2 P29597 1/20 0.48
CSNK1D P48730 1/20 0.48
CDK7 P50613 1/20 0.48
CDK9 P50750 1/20 0.48
LIMK1 P53667 1/20 0.48
CDK16 Q00536 1/20 0.48
MAPK7 Q13164 1/20 0.48
CDK13 Q14004 1/20 0.48
PRKD1 Q15139 1/20 0.48
RPS6KA1 Q15418 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818602 0.91 IKBKB (0.47) IKBKBCHUKERN1RPS6KA4PRKD3
SCHEMBL2814867 0.89 IKBKB (0.61) IKBKBCHUKSYKERN1RPS6KA4
SCHEMBL2818040 0.86 IKBKB (0.48) IKBKBCHUKSYKERN1RPS6KA4
SCHEMBL2820826 0.86 IKBKB (0.48) IKBKBCHUKERN1RPS6KA4PRKD3
SCHEMBL2817629 0.86 IKBKB (0.48) IKBKBCHUKSYKERN1RPS6KA4
SCHEMBL2819760 0.86 IKBKB (0.48) IKBKBCHUKSYKERN1RPS6KA4
SCHEMBL2813901 0.85 IKBKB (0.51) IKBKBCHUKSYKERN1RPS6KA4
SCHEMBL2817059 0.85 MAPT (0.47) IKBKBCHUKSYKMAPTADORA3
SCHEMBL2818783 0.83 IKBKB (0.46) IKBKBCHUKERN1RPS6KA4PRKD3
SCHEMBL2817052 0.83 IKBKB (0.59) IKBKBCHUKERN1RPS6KA4PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP claimed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US claimed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS IKBKB 855/4885CHUK 409/4885SYK 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.